Multidisciplinary Journal of Science and Technology

DIAGNOSTIC VALUE OF NON-INVASIVE TESTS IN LIVER CIRRHOSIS

R.Z. Umurzaqova

Associate Professor, PhD

Sh.F. Ubaydullayeva

Master’s Student, 1st Year, Laboratory Work) Department of Hospital Therapy and Endocrinology, Andijan State Medical Institute, Andijan, Uzbekistan.

Keywords: Liver cirrhosis, Non-invasive tests, Hepatic fibrosis, FIB-4 index, APRI score, Biomarkers, Hepatology.

---

Abstract

Liver cirrhosis is an end-stage manifestation of chronic liver diseases, contributing significantly to global morbidity and mortality. While liver biopsy remains the historical gold standard for staging fibrosis, its invasiveness, cost, and potential complications necessitate the integration of reliable non-invasive tests (NITs). This study aims to evaluate the diagnostic accuracy and clinical utility of serum-based non-invasive scoring systems, specifically the AST to Platelet Ratio Index (APRI) and the Fibrosis-4 (FIB-4) index, in identifying liver cirrhosis within the population of the Fergana Valley. A cross-sectional observational study was conducted involving 110 participants, comprising 75 patients with clinically and sonographically confirmed liver cirrhosis and 35 healthy controls. Routine laboratory parameters, including complete blood counts and liver function tests, were analyzed to calculate APRI and FIB-4 scores. Statistical evaluation utilized the Student’s t-test and diagnostic performance metrics (sensitivity, specificity). The results demonstrated a highly significant elevation of both scores in the cirrhotic cohort. The mean APRI score in cirrhotic patients was 1.85 ± 0.22 compared to 0.32 ± 0.05 in controls (p < 0.001). Similarly, the FIB-4 index was profoundly elevated (4.85 ± 0.55 vs. 0.95 ± 0.12, p < 0.001). Using a cut-off of >3.25, FIB-4 exhibited a sensitivity of 82% and a specificity of 89% for detecting advanced cirrhosis. Serum-based non-invasive tests, particularly the FIB-4 index, offer a highly accurate, cost-effective, and safe alternative to biopsy. Their routine implementation in regional primary care settings is critical for the early identification, risk stratification, and timely management of patients with progressive liver disease.

---

References

1. European Association for the Study of the Liver (EASL). (2015). EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology, 63(1), 237-264. DOI: 10.1016/j.jhep.2015.04.006

2. Wai, C. T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S. (2003). A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 38(2), 518-526. DOI: 10.1053/jhep.2003.50346

3. Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., ... & APRICOT Clinical Investigators. (2006). Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 43(6), 1317-1325. DOI: 10.1002/hep.21178

4. Vallet-Pichard, A., Mallet, V., Nalpas, B., Verkarre, V., Nalpas, A., Dhalluin-Venier, V., ... & Pol, S. (2007). FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology, 46(1), 32-36. DOI: 10.1002/hep.21669

5. Castera, L., Friedrich-Rust, M., & Loomba, R. (2019). Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology, 156(5), 1264-1281. DOI: 10.1053/j.gastro.2018.12.036

6. Boursier, J., de Ledinghen, V., Zarski, J. P., Fouchard-Hubert, I., Gallois, Y., Oberti, F., ... & Multicentric Group from SNFGE. (2012). Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology, 55(1), 58-67. DOI: 10.1002/hep.24654

7. Crossan, C., Tsochatzis, E. A., Longworth, L., Gurusamy, K. S., Rodriguez-Peralvarez, M., Mantzoukis, K., ... & Burroughs, A. K. (2015). Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technology Assessment, 19(9), 1-409. DOI: 10.3310/hta19090

8. Shaheen, A. A., & Myers, R. P. (2007). Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology, 46(3), 912-921. DOI: 10.1002/hep.21835

9. Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014). Liver cirrhosis. The Lancet, 383(9930), 1749-1761. DOI: 10.1016/S0140-6736(14)60121-5

10. Tapper, E. B., & Lok, A. S. (2017). Use of liver imaging and biopsy in clinical practice. New England Journal of Medicine, 377(8), 756-768. DOI: 10.1056/NEJMra1610570